Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cardiomyopeptidin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Chinese PLA General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cardiomyopeptidin is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Cardiomyopeptidin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Chinese PLA General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
